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Alzheimer’s disease remains a formidable challenge for therapeutic management. In a recent report inNature
Structural and Molecular Biology, Cohen et al. (2015) present intriguing results showing that ‘‘designer’’
molecular chaperones may hold the key to an evolutionarily conserved program for management of toxic
oligomer species contributing to brain pathobiology.While functional amyloid is a major
component of normal biological pro-
cesses across diverse species (Fowler
et al., 2007), diseases associated with
systemic and neurodegenerative fibril
accumulation span a spectrum of over
40 amyloid-related disorders. These
include Alzheimer’s disease (AD), which
is triggered by the aberrant processing
of the amyloid precursor protein (APP),
a protein essential in development, to
Ab peptides. While our understanding
of Ab amyloid precursor biochemistry,
biophysics, and its cell (patho)biology
continue to advance, these insights have
failed to deliver drugs to the clinic, likely
reflecting our lack of understanding of
the critical events responsible for pro-
gression of AD pathology. A new view
of amyloid deposition stems from the
realization that the protein fold does not
operate in isolation and that the intrinsic
dynamics of amyloid-prone protein struc-
tures need to be continually assisted by
an evolutionarily conserved and pervasive
folding management program termed
proteostasis (Balch et al., 2008). Proteo-
stasis encompasses a vast network of
chaperones and degradation pathways
that operate using integrative cell-autono-
mous and non-cell-autonomous net-
works (Wolff et al., 2014). The proteostatis
network regulates protein structure-func-
tion relationships encoded in the primary
sequence in response to diverse environ-
ments impacting both the secondary and
tertiary folding elements and the newly
recognized surface weak forces defined
by the quinary or Q-state proteostasis
buffering capacity (Hingorani and Gier-
asch, 2014; Roth et al., 2014). Cohen
et al. (2015) have now defined the mecha-
nism of action of a specific extracellularanti-amyloid chaperone, the Brichos
domain (Knight et al., 2013). Identification
of proteostatic sensitive ‘‘hotspots’’ in
amyloid fibrils catalytically triggering olig-
omer assembly could be a turning point
not only in our understanding of functional
amyloid, but also in approaches to thera-
peutically mitigate the progression of
amyloid disease in the clinic.
Past efforts directed toward under-
standing the biochemistry and biophysics
of amyloid formation have revealed a
complex mechanism of fibril assembly
that includes a concentration-dependent
rate-limiting nucleation step involving
small oligomer species, followed by a
rapid polymerization step that gives rise
to fibrils that lead to amyloid plaques in
the extracellular space of the brain
(Figure 1). Fibril-rich plaques are no longer
considered the smoking gun in pathogen-
esis of AD, and this role has shifted to
small oligomers, with the caveat that toxic
initiating oligomers may not be generated
in sufficient numbers to account for the
pathogenicity observed in disease. New
evidence suggests that a second tier of
nucleation sites is found along the sur-
face of the growing fibril. These sites
are thought to function catalytically to
nucleate and accelerate toxic small olig-
omer generation at the expense of fibril
elongation (Figure 1). Given the high pro-
pensity of most proteins to form amyloid,
it has been proposed that endogenous
mechanisms must exist to protect cells
and the organism from rampant small
oligomer amyloid toxicity. To address
this concern, Cohen et al. (2015) have
focused on defining the mechanism of
action of the Brichos domain, a 100 aa
peptide domain found in many protein
families, including the abundant secretedDevelopmental Cell 3proprotein family proteins (Knight et al.,
2013). The Brichos domain, when
mutated, has been implicated in multiple
prion diseases. Intriguingly, Brichos do-
mains have been previously proposed
to have targeted anti-amyloid activity
(Knight et al., 2013), and thus it functions
as an amyloid-specific chaperone con-
trolling amyloid deposition. While proteo-
stasis-based chaperone biology is well
recognized for its role in protein folding
and in preventing aggregation, the poten-
tial mechanism by which a native anti-
amyloid domain such as Brichos operates
remains unknown. Using methods to
quantitate Ab-fibril formation in vitro
involving purified monomeric Ab as a
starting point, the authors tested the
potential impact of the purified Brichos
domain found in proSP-C (a heavily
secreted lung surfactant involved in
interstial lung disease [ILD]) on the rate-
limiting primary nucleation step respon-
sible for the formation of the initiating toxic
oligomer species, the rapid fibril exten-
sion step, and the secondary nucleation
sites found on growing fibrils (Figure 1).
Curiously, Brichos did not bind mono-
meric species of Ab, and neither the
rate-limiting primary nucleation event nor
the kinetics of assembly monomers on
the ends of existing fibrils promoting
fibril growth were affected by Brichos.
However, Brichos bound to fibrils and
inhibited the secondary nucleation events
responsible for the rapid, catalytic gener-
ation of the toxic oligomeric species. The
ability of Brichos to associate with exist-
ing amyloid fibrils was confirmed by
transmission electron microscopy (TEM).
Interestingly, with secondary nucleation
events blocked, fibril growth was pro-
moted, leading to extended structures2, March 23, 2015 ª2015 Elsevier Inc. 659
Figure 1. Proteostatic Hotspot Control of Native and Pathogenic Amyloid
Illustrated is the impact of designer amyloid chaperones (green, blue pentamers) on proteostatic hotspots
(red stars) found in polymer fibrils assembled frommonomers (black spheres) catalytically nucleating toxic
oligomer formation. Therapeutic management of proteostatic hotspots triggering dementia may be treat-
able by hotspot-targeted therapeutics (orange chevrons).
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considerably reduce the toxic effects of
small oligomeric amyloid species on syn-
aptic function in brain slices. Because the
accumulation of oligomers is currently
thought to be the toxic species driving
disease progression, the ability of Brichos
to promote extension of existing fibrils
while simultaneously limiting toxic olig-
omer formation may limit progression,
addressing a long-standing conundrum
in AD biology (Figure 1).
It now appears that the Brichos domain
belongs to an emerging family of designer
chaperones, including the collagen-spe-
cific chaperone Hsp47, or chaperones
secreted by bacteria into the extracellular
environment to manage filament forma-
tion in bacteria (Powers and Balch,
2011). Indeed, the activity of Brichos is
reminiscent of the ability of transthyretin
(TTR), an abundant extracellular protein
secreted from the liver and the choroid
plexus, which has also been shown to
reduce Ab aggregation (Li et al., 2013).
Brichos and related amyloid chaperone
managers belong to what we have660 Developmental Cell 32, March 23, 2015 ªdefined as the ‘‘outside’’ proteostatic
network (Powers and Balch, 2011). The
ability of the Brichos domain to inhibit
toxic oligomer formation via secondary
nucleation raises the possibility that puri-
fied Brichos domains, synthetic peptide
mimetics, and/or a monoclonal antibody
mimetic with identical targeting specificity
could block or slow dementia (Figure 1,
orange chevron). Given the many compli-
cations of delivery of biologics to the
brain, a better strategy could be the iden-
tification of small molecules that target
the protein interface defined by the pro-
teostatic hotspot managed by the
designer Brichos domain activity in the
growing amyloid fibril.
It is likely that efforts by Cohen et al.
(2015) represent the tip of the proteosta-
sis ‘‘iceberg’’ managing protein folding
for delivery outside the cell (Powers and
Balch, 2011), raising the possibility that
many undiscovered factors found in the
proteostasis network may prevent dis-
ease by managing secreted amyloido-
genic species in health (Fowler et al.,
2007) and could be leveraged for disease,2015 Elsevier Inc.a thought consistent with the newly
recognized importance of the proteostatis
network as both a general and specific
driver of protein structure-function rela-
tionships, reflecting their clear role in
driving evolutionary diversity (Powers
and Balch, 2013). We now need to define
the endogenous role(s) of this growing
class of extracellular chaperones in regu-
lating functional and disease-causing
amyloid. Moreover, the potential for
small-molecule and/or brain-penetrant
biologic drugs that target the ‘‘proteo-
static hotspots’’ on amyloid fibrils that
decrease secondary nucleation, toxic
oligomer burden, and dementia progres-
sion remains to be explored. An exciting
challenge would be to determine whether
proteostatic hotspot drugs synergize with
currents efforts to prevent aberrant APP
cleavage to Ab. With an understanding
of the mechanisms by which the anti-am-
yloid activity of divergent Brichos and
related domains may function (Knight
et al., 2013), we may be poised to jump-
start a new generation of proteostatic hot-
spot dementia therapeutics.REFERENCES
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